Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases

Human Mutation

Volumn 33, Issue 11, 2012, Pages 1566-1575

  Hashimoto, Kosuke ^a,b   Rogozin, Igor B ^a   Panchenko, Anna R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b RIKEN   (Japan)

Author keywords

Cancer mutation; Double mutations; Kinase activation; Mutation spectra; Protein structure; Receptor tyrosine kinase

Indexed keywords

MUTANT PROTEIN; PROTEIN TYROSINE KINASE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL; CARCINOGENICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STABILITY; EPISTASIS; HUMAN; NEOPLASM; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

DATABASES, GENETIC; ENZYME ACTIVATION; ENZYME STABILITY; EPISTASIS, GENETIC; GENE REGULATORY NETWORKS; GENES, ERBB-1; HUMANS; MUTATION; NEOPLASMS; ONCOGENES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84867468266     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22145     Document Type: Article

References (71)

1. Adams WT, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. J Mol Biol 194:391-396.
2. Bazykin GA, Kondrashov FA, Ogurtsov AY, Sunyaev S, Kondrashov AS. 2004. Positive selection at sites of multiple amino acid replacements since rat-mouse divergence. Nature 429:558-562.
3. Buettner VL, Hill KA, Scaringe WA, Sommer SS. 2000. Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events. Mutat Res 452:219-229.
4. Chen JM, Ferec C, Cooper DN. 2009. Closely spaced multiple mutations as potential signatures of transient hypermutability in human genes. Hum Mutat 30:1435-1448.
5. Chen JM, Ferec C, Cooper DN. 2012. Transient hypermutability, chromothripsis and replication-based mechanisms in the generation of concurrent clustered mutations. Mutat Res 750:52-59.
6. Chen Z, Feng J, Buzin CH, Sommer SS. 2008. Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events. PLoS One 3:e3714.
7. Crow JF. 1999. Hardy, Weinberg and language impediments. Genetics 152:821-825.
8. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. 1993. Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602.
9. Dixit A, Torkamani A, Schork NJ, Verkhivker G. 2009a. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J 96:858-874.
10. Dixit A, Verkhivker GM. 2009. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol 5:e1000487.
11. Dixit A, Verkhivker GM. 2011. The energy landscape analysis of cancer mutations in protein kinases. PLoS One 6:e26071.
12. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork NJ, Verkhivker GM. 2009b. Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One 4:e7485.
13. Drake JW, Bebenek A, Kissling GE, Peddada S. 2005. Clusters of mutations from transient hypermutability. Proc Natl Acad Sci U S A 102:12849-12854.
14. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, et al. 2007. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932.
15. Eswaran J, Knapp S. 2010. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim Biophys Acta 1804:429-432.
16. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. 2008. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:unit10.11.
17. Glazko GB, Milanesi L, Rogozin IB. 1998. The subclass approach for mutational spectrum analysis: application of the SEM algorithm. J Theor Biol 192:475-487.
18. Glazko GV, Babenko VN, Koonin EV, Rogozin IB. 2006. Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection. Biol Direct 1:4.
19. Goto N, Prins P, Nakao M, Bonnal R, Aerts J, Katayama T. 2010. BioRuby: bioinformatics software for the Ruby programming language. Bioinformatics 26:2617-2619.
20. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
21. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313.
22. Guerois R, Nielsen JE, Serrano L. 2002. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 320:369-387.
23. Hardy GH. 1908. Mendelian proportions in a mixed population. Science 28:49-50.
24. Hill KA, Wang J, Farwell KD, Scaringe WA, Sommer SS. 2004. Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency. Mutat Res 554:223-240.
25. Hubbard SR, Miller WT. 2007. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19:117-123.
26. Hurst LD. 2002. The Ka/Ks ratio: diagnosing the form of sequence evolution. Trends Genet 18:486.
27. Izarzugaza JM, Redfern OC, Orengo CA, Valencia A. 2009. Cancer-associated mutations are preferentially distributed in protein kinase functional sites. Proteins 77:892-903.
28. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. 2009. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267-5273.
29. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-320.
30. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. 2011. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42:9-22.
31. Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D, Stinson J, Forrest WF, Bazan JF, Seshagiri S, Zhang Z. 2007. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 67:465-473.
32. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. 2004. The KEGG resource for deciphering the genome. Nucleic Acids Res 32:D277-D280.
33. Katoh K, Toh H. 2008. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 9:286-298.
34. Khan S, Vihinen M. 2010. Performance of protein stability predictors. Hum Mutat 31:675-684.
35. Khromov-Borisov NN, Rogozin IB, Pegas Henriques JA, de Serres FJ. 1999. Similarity pattern analysis in mutational distributions. Mutat Res 430:55-74.
36. Kornev AP, Haste NM, Taylor SS, Eyck LF. 2006. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A 103:17783-17788.
37. Martin GS. 2004. The road to Src. Oncogene 23:7910-7917.
38. Matsuda T, Bebenek K, Masutani C, Rogozin IB, Hanaoka F, Kunkel TA. 2001. Error rate and specificity of human and murine DNA polymerase eta. J Mol Biol 312:335-346.
39. Meng L, Lin L, Zhang H, Nassiri M, Morales AR, Nadji M. 1999. Multiple mutations of the p53 gene in human mammary carcinoma. Mutat Res 435:263-269.
40. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, Miller WT. 1997. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385:650-653.
41. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
42. Pavlov YI, Shcherbakova PV, Rogozin IB. 2006. Roles of DNA polymerases in replication, repair, and recombination in eukaryotes. Int Rev Cytol 255:41-132.
43. Potapov V, Cohen M, Schreiber G. 2009. Assessing computational methods for predicting protein stability upon mutation: good on average but not in the details. Protein Eng Des Sel 22:553-560.
44. Reva B, Antipin Y, Sander C. 2011. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118.
45. Rodin SN, Rodin AS. 1998. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc Natl Acad Sci U S A 95:11927-11932.
46. Rogozin I, Kondrashov F, Glazko G. 2001. Use of mutation spectra analysis software. Hum Mutat 17:83-102.
47. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
48. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Federhen S, Feolo M, Fingerman IM, et al. 2011. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 39:D38-D51.
49. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942.
50. Schuster-Bockler B, Bateman A. 2008. Protein interactions in human genetic diseases. Genome Biol 9:R9.
51. Seidman MM, Bredberg A, Seetharam S, Kraemer KH. 1987. Multiple point mutations in a shuttle vector propagated in human cells: evidence for an error-prone DNA polymerase activity. Proc Natl Acad Sci U S A 84:4944-4948.
52. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498-2504.
53. Sordella R, Bell DW, Haber DA, Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167.
54. Stone JE, Kissling GE, Lujan SA, Rogozin IB, Stith CM, Burgers PM, Kunkel TA. 2009. Low-fidelity DNA synthesis by the L979F mutator derivative of Saccharomyces cerevisiae DNA polymerase zeta. Nucleic Acids Res 37:3774-3787.
55. Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP. 2009. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 8:2142-2151.
56. Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, et al. 2009. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene 28:518-533.
57. Teng S, Madej T, Panchenko A, Alexov E. 2009. Modeling effects of human single nu-cleotide polymorphisms on protein-protein interactions. Biophys J 96:2178-2188.
58. Tokuriki N, Tawfik DS. 2009. Stability effects of mutations and protein evolvability. Curr Opin Struct Biol 19:596-604.
59. Torkamani A, Verkhivker G, Schork NJ. 2009. Cancer driver mutations in protein kinase genes. Cancer Lett 281:117-127.
60. Vogelstein B, Kinzler KW. 1993. The multistep nature of cancer. Trends Genet 9:138-141.
61. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867.
62. Weinstein IB. 2002. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297:63-64.
63. Weinstein IB, Joe A. 2008. Oncogene addiction. Cancer Res 68:3077-3080.
64. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, et al.. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
65. Yue P, Li Z, Moult J. 2005. Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol 353:459-473.
66. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. 2007. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227.
67. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. 2008. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070-2075.
68. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
69. Zhang Z, Norris J, Schwartz C, Alexov E. 2011. In silico and in vitro investigations of the mutability of disease-causing missense mutation sites in spermine synthase. PLoS One 6:e20373.
70. Zhang Z, Teng S, Wang L, Schwartz CE, Alexov E. 2010. Computational analysis of missense mutations causing Snyder-Robinson syndrome. Hum Mutat 31:1043-1049.
71. Zhang Z, Wang L, Gao Y, Zhang J, Zhenirovskyy M, Alexov E. 2012. Predicting folding free energy changes upon single point mutations. Bioinformatics 28:664-671.